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Determination of the minimum inhibitory concentration (MIC)
of a drug that prevents microbial growth is an important step for
managing patients with infections. In this paper we present a novel
probabilistic approach that accurately estimates MICs based on a
panel of multiple curves reflecting features of bacterial growth. We
develop a probabilistic model for determining whether a given dilu-
tion of an antimicrobial agent is the MIC given features of the growth
curves over time. Because of the potentially large collection of fea-
tures, we utilize Bayesian model selection to narrow the collection
of predictors to the most important variables. In addition to point
estimates of MICs, we are able to provide posterior probabilities that
each dilution is the MIC based on the observed growth curves. The
methods are easily automated and have been incorporated into the
Becton–Dickinson PHOENIX automated susceptibility system that
rapidly and accurately classifies the resistance of a large number of
microorganisms in clinical samples. Over seventy-five studies to date
have shown this new method provides improved estimation of MICs
over existing approaches.
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1. Introduction. Since the discovery of penicillin in the late 19th cen-
tury, microbiology has undergone rapid development. Large numbers of an-
tibiotics have been identified and have greatly improved the management of
patients with infectious diseases. Antimicrobial susceptibility testing (AST)
of clinically obtained isolates4 is performed daily across the world. Through
such tests, the activity of an antimicrobial agent against an organism, such
as bacteria, is reported either quantitatively or qualitatively. Quantitative
microbial inhibitory activity is typically described in terms of the minimum
inhibitory concentration (MIC), which is defined as the lowest concentration
of an antimicrobial agent at which bacterial growth is inhibited in in-vitro
testing. In the U.S. the Clinical and Laboratory Standards Institute [CLSI
(2008)] establish MIC breakpoints for a given bacterial species and antibi-
otic so that an isolate may be classified as “susceptible” (S) if the MIC
is less than or equal to the lower breakpoint, “resistant” (R) if the MIC
is greater than or equal to the higher breakpoint, or “intermediate” (I) if
the MIC falls in between. Isolates in the susceptible category are inhibited
by the usually achievable concentrations of antimicrobial agent when the
recommended dosage is used for the site of infection, while isolates in the
resistant group are not inhibited by the usually achievable concentrations of
the agent with normal dosage schedules; the intermediate classification pro-
vides a buffer zone for uncontrolled variation or where the antibiotic may be
effective at higher than normal doses. Results of such testing are then used to
predict treatment outcome with the antimicrobial agents tested and guide
clinicians in selecting the most appropriate agent for a particular clinical
problem [Turnidge, Ferraro and Jorgensen (2003)].
Current reference methods for antimicrobial susceptibility testing, such as
dilution or disk diffusion, are predominantly phenotypic approaches based on
growth patterns of micro-organisms in antimicrobial agents [Wheat (2001)].
Dilution susceptibility testing methods are quantitative methods that de-
termine the MIC by exposing the isolate to a series of two-fold dilutions of
the antimicrobial agent (e.g., 1 µg/mL, 2 µg/mL, 4 µg/mL, 8 µg/mL, 16
µg/mL, etc.) in a suitable culture system, such as broth or agar, on a series
of plates or tubes. Typically, eight or more concentrations of an agent are
used, although the range of concentrations tested depends on the antimi-
crobial agent and species being tested. These are incubated overnight and
each tube or plate is visually inspected for growth; the lowest dilution in
which the isolate does not grow is reported as the MIC [see Jorgensen and
Turnidge (2003), CLSI (2006) for detailed discussion and methods]. Includ-
ing preparation time, incubation time and analysis, it may take 24–48 hours
to provide results.
4A population of bacteria or other cells that has been isolated.
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In recent years, efforts for speeding up the process of susceptibility test-
ing have resulted in the development of automated AST systems [Ferraro
and Jorgensen (2003)]. In an automated system, it is feasible to monitor the
growth of isolates in real time; by utilizing the information in the growth
curves corresponding to the series of dilutions, it is possible to make an early
determination of the MIC (in a couple of hours ideally), providing a dra-
matic decrease in the time to results compared to reference methods that
make a determination at a fixed end-point. Given the critical importance
of rapid and accurate identification of micro-organisms and especially their
drug resistance in the management of patients, automation of the testing
process and rapid reporting of results is of great clinical and financial bene-
fit to patients and hospitals [Barenfanger, Drake and Kacich (1999)]. With
automation, a large number of tests can be performed simultaneously, lead-
ing to a substantial increase in the amount of data to be analyzed. Thus,
there is a crucial need for such automated systems to be coupled with rig-
orous statistical methods that produce reliable MIC estimates in real-time.
In this paper we develop a novel statistical method that allows accurate
and rapid determination of MICs based on a panel of growth curves for a
given isolate exposed to various dilutions of an antimicrobial agent. This
methodology is currently implemented in Becton–Dickinson’s (BD) newly
developed PHOENIX AST system (BD Diagnostic Systems, Sparks, MD).
This system provides rapid and reliable susceptibility testing of a majority
of clinically encountered bacterial strains and is currently utilized by a large
number of laboratories across the globe.
In the next section we describe the structure of the panel growth data
obtained during the development of the BD PHOENIX AST system. Our
goal is to identify and use features of the growth curves to accurately pre-
dict the MIC for each set of panel data. In order to train the statistical
algorithms, in Section 3 we develop a model that predicts for each concen-
tration a growth or no growth response, using available features of the curves
from each panel. Features in the growth data that are crucial for predict-
ing the probability of growth are selected using Bayesian model selection.
For each isolate and drug dilution in a panel, we construct an estimate of
the probability of growth using these selected features of the growth curves.
In Section 4 we present a novel method to combine the estimated growth
probabilities for the sequence of drug dilutions in a panel to construct a
probability distribution for the MIC. A decision theoretic approach for esti-
mating the MIC is presented which balances the different types of errors in
making an MIC call. In Section 5 we validate the method and illustrate its
performance using two selected antibiotics, piperacillin (PIP) and cefoxitin
(FOX). We conclude with discussion in Section 6.
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2. The PHOENIX AST system. PHOENIX is an instrumented antimi-
crobial susceptibility testing (AST) system for rapid identification and sus-
ceptibility determination of bacterial isolates from clinical samples. In this
system a bacterial suspension is placed in a series of wells (typically eight)
on a test panel, where each panel is a single PHOENIX diagnostic dispos-
able cartridge. Each well in a panel corresponds to a different dilution of
the microbial agent being tested. Multiple panels are placed in a revolving
carousel and at a sequence of twenty minute intervals the system moves the
panels past a detector where red, green and blue wavelengths are directed
at each well. The system measures the wavelengths that emanate from the
wells; these optical measurements are used to generate two measures of mi-
crobial growth: the redox state and turbidity characteristics of the sample
wells which are directly correlated with microbial growth. The redox state
of a sample in a well is measured by utilizing the change in red, green and
blue readings that occurs over time as a result of the reduction of a growth
indicator, such as resazurin, by the microbial material in the well. As the
resazurin is reduced, the color of the sample in the well changes from blue
to red to clear. This change in redox is represented numerically as a con-
tinuum, with the value 0 indicating an unreduced growth indicator (blue =
resazurin), the value 0.5 indicating that the indicator is 50% reduced (red),
and the value 1.0 indicating that the indicator has been completely reduced
(clear = dihydroresorufin). The turbidity is also estimated by using the red,
green and blue readings. The initial signal has a value of 0 and a maximum
of 2.25 (McFarland) units can be estimated.
The system monitors growth over time to decide if the samples have incu-
bated long enough to estimate the MIC. If the processor determines that the
maximum redox state for the growth control well of the test panel is greater
than 0.07 but less than a predetermined value of 0.2, the panel continues
to be incubated, as this implies insufficient growth. If the processor deter-
mines that the maximum redox state for the growth control well is indeed
greater than 0.2, the processor then checks whether a call can be made. If
the processor determines that the redox curve for the growth control well
indicates that the sample is not yet classifiable as either a slow or fast grow-
ing sample, the panel incubation continues and the panel is retested twenty
minutes later. If the processor determines that the redox curve classification
is either fast or slow growing, the time at which this occurs is labeled as the
“time-to-result” and the turbidity and redox data for each of the wells in the
panel are extracted. If the incubation period exceeds 16 hours, the test panel
is reported as “failed” for having insufficient sample growth in the allotted
time, and no results are reported for that test panel. A second-degree poly-
nomial local regression algorithm (LOESS) is used to smooth the time series
data for both redox and turbidity values calculated for each well over the
elapsed period of time. From the LOESS fit any reading at any time point
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can be estimated. Moreover, first- and second-derivatives can be estimated
at any point as a function of fitted local regression coefficients.
Figure 1 illustrates these interpolated growth curves for three PHOENIX
panels in which three gram-negative bacterial strains were combined with the
following dilutions of the drug piperacillin (PIP): 0.25 µg/mL, 0.5 µg/mL,
1 µg/mL, 2 µg/mL, 4 µg/mL, 8 µg/mL, 16 µg/mL, 32 µg/mL, 64 µg/mL
and 128 µg/mL.
Each row of plots shows the growth response of a single isolate to varying
dilutions of PIP, and was selected to show the range of responses. For a
given plot, each curve corresponds to a different dilution of the drug PIP.
The vertical line represents the time-to-result, the time at which features
are extracted for determining the MIC. Independently from the PHOENIX
AST system, a reference MIC is determined for each strain using broth
micro-dilution susceptibility testing with the same series of two-fold dilutions
[CLSI (2006)]. In Figure 1 curves corresponding to dilutions less than the
reference MIC are dashed lines, while all curves with dilutions greater than
the reference MIC are solid. The dilution corresponding to the reference
MIC is represented with a long and short dashed line.
3. Modeling probability of growth. Theoretically, we should see no growth
in a well with a concentration higher than the true MIC. Using the exter-
nal reference value of the MIC, we create a binary response variable Yij for
dilution j in panel i defined as
Yij =
{
1, if dilution j is ¡ reference MIC,
0, if dilution j is ≥ reference MIC.
This definition treats the reference MIC data as if it were measured without
error and ignores any possible missclassifications of curves. The reference
methods are discrete measurements of what is in reality a value along a
continuum. The error associated with any individual MIC estimate will be
affected by many factors; these include but are not limited to operator error,
variation in the materials utilized and the isolate and antimicrobial agent be-
ing tested. Multiple observations with a specific bacterial isolate and antimi-
crobial combination will typically be normally distributed around a modal
MIC value, with 60–80% of the observations being at the modal MIC value
[CLSI (2006)]. Conventionally, any two observations within ± one two-fold
dilution are considered to be in agreement (this corresponds to a one unit
change on the log base 2 scale). For our purposes, we will treat the reference
MIC estimate as the truth, as this is the best available information.
Inspection of the panels in the third row of Figure 1 indicates that sev-
eral curves with dilutions above the reference MIC exhibit growth in both
the redox and turbidity responses for strain 14,617. For strain 14,598 (the
second row), the redox curves also show evidence of growth at dilutions
6 X. K. ZHOU ET. AL.
Fig. 1. Panel data for three gram-negative bacterial strains exposed to dilutions of
piperacillin (PIP) showing turbidity (a) and redox (b) over time in hours. The verti-
cal line is at the time-to-result when features are extracted for estimating the MIC. Dashed
curves have concentrations less than the reference MIC, while solid lines have concentra-
tions greater than or equal to the reference MIC. The curve with dilution equal to the
reference MIC is depicted with long–short dashes.
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above the reference MIC; the turbidity measurements for dilutions above
the MIC, while still increasing, are well separated from the curves above
the MIC. Upon further verification, the problem for these two isolates is
not attributed to an error in the reference MIC data, but attributed to the
PHOENIX measurements (also subject to operator error, variation in ma-
terials such as formulation of the panels5 and variation in the isolate). The
predictive accuracy of the training model may be improved through an it-
erative procedure by omitting such “outlier” panels that exhibited strong
growth for dilutions above the MIC when the reference MIC could be veri-
fied as being correct. Because such iterative “outlier” analysis could not be
conducted for model training with additional agents tested at BD, we chose
to include such cases in our analyses.
3.1. Models. Conditional on the unknown probabilities (and MIC), we
assume that indicators of growth in different wells and across panels are
independent of each other,
Yij | piij
ind
∽ Ber(piij), i= 1, . . . , n, j = 1, . . . , J,(3.1)
where piij is the probability of growth or, equivalently, that dilution j in
panel i is less than the MIC, n is the number of panels, and J is the number
of dilutions or wells in a panel. While it is conceivable that observations
in the same panel may be dependent, the model in (3.1) implies that such
dependence may be captured through the model for the probabilities piij ,
for example, a panel specific random effect.
The indicator of GROWTH/NO GROWTH may be predicted as a func-
tion of the growth curves by modeling the probabilities of growth, piij , as
a function of the time series for dilution j in panel i. While of course the
entire time series could be used for modeling the GROWTH indicators,
certain features of the curves may be sufficient for differentiating the pat-
tern of GROWTH/NO GROWTH. In an experiment with no noise in the
growth curves, we would actually need only the difference in growth mea-
surements from the beginning to the time-to-result to separate the dilutions
corresponding to GROWTH or NO GROWTH. However, with noisy curves,
other features may be better predictors of growth. In Table 1 we list the
features of the curves that were viewed as being scientifically relevant for
predicting growth. These include the difference in growth, the area under the
growth curve, the first derivative, the second derivative at the time-to-result
and time points where maxima occurred. Most features are defined relative
to the growth control well to standardize them across different isolate/drug
combinations.
5The experimental data presented here were from the early stages of development of the
PHOENIX system; BD has reformulated panels since our initial analysis was conducted.
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Table 1
Characteristic features of growth curves used as covariates in the GROWTH or NO
GROWTH model
Feature label Description
T.FD Turbidity, 1st derivative of the Test Well
T.SD Turbidity, 2nd derivative of the Test Well
T.IN Turbidity, Integral of the Test Well
T.AB.M Turbidity, Maximum Absolute of the Test Well
T.FD.M Turbidity, Maximum 1st Derivative of the Test Well
T.SD.M Turbidity, Maximum 2nd Derivative of the Test Well
T.AB.M.R T.AB.M(Test Well)/T.AB.M(Control Well)
T.FD.M.R T.FD.M(Test Well)/T.FD.M(Control Well)
T.SD.M.R T.SD.M(Test Well)/T.SD.M(Control Well)
T.IN.R T.IN(Test Well)/T.AB(Control Well)
T.FD.T tT.FD.M(Test Well)−tT.FD.M(Control Well)
T.SD.T tT.SD.M(Test Well)−tT.SD.M(Control Well)
R.FD Redox, 1st derivative of the Test Well
R.SD Redox, 2nd derivative of the Test Well
R.IN Redox, Integral of the Test Well
R.AB.M Redox, Maximum Absolute of the Test Well
R.FD.M Redox, Maximum 1st Derivative of the Test Well
R.SD.M Redox, Maximum 2nd Derivative of the Test Well
R.AB.M.R R.AB.M(Test Well)/R.AB.M(Control Well)
R.FD.M.R R.FD.M(Test Well)/R.FD.M(Control Well)
R.SD.M.R R.SD.M(Test Well)/R.SD.M(Control Well)
R.IN.R R.IN(Test Well)/R.AB(Control Well)
R.FD.T tR.FD.M(Test Well)−tR.FD.M(Control Well)
R.SD.T tR.SD.M(Test Well)−tR.SD.M(Control Well)
We use a logistic regression model, a generalized linear model, to relate
the GROWTH indicator to the collection of features, where the linear pre-
dictor ηij ≡ logit(piij)≡ log(piij/(1−piij)) is expressed as a linear function of
selected features. As we are uncertain that the relationship is actually linear
in the features in Table 1, we may try more flexible generalized linear models
where we replace the linear functions by up to a third order polynomial in
each feature. As the linear, quadratic and cubic terms are typically highly
correlated with each other, orthogonal polynomials are preferable from a
computational perspective for model selection, but give equivalent predic-
tions. More generally, the generalized linear model can be represented in
matrix notation as η =Xβ, where X represents the n× p matrix of feature
variables with columns for the linear, quadratic and cubic terms, β is the
p dimensional vector of the unknown regression coefficients and η is the
n-dimensional vector of the linear predictor. Once we have estimates of β,
these are used to calculate ηˆij , the estimate of the linear predictor, which in
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turn is used to obtain the estimates of the probabilities of GROWTH,
pˆiij =
exp(ηˆij)
1 + exp(ηˆij)
.
We may find that not all features are needed to model the probability of
GROWTH; the variables represent features that could potentially explain
the growth patterns and in some cases may be redundant. Using all features
(and the higher polynomial terms) may lead to over-fitting of the model
training data and poor predictions on the out-of-sample validation data.
Reducing the set of features is also important because of limited storage and
computing capacity in the system for making predictions. Bayesian variable
selection [Hoeting et al. (1999), Clyde and George (2004)] can be used to
reduce the set of features to prevent over-fitting while still providing excellent
out-of-sample properties.
3.2. Bayesian model selection. We used Bayesian model selection based
on the Bayes Information Criterion [Schwarz (1978), Kass and Raftery (1995)]
to reduce the set of features used in the prediction of GROWTH. This ap-
proach is equivalent to using a penalized deviance criterion for model selec-
tion, however, the penalty depends on the sample size, which ensures that
in large samples that the probability of the true model goes to one (un-
der modest conditions), and provides consistent model selection [Kass and
Raftery (1995)]. This choice typically results in more parsimonious models
than selection based on, for example, the often-used Akaike’s Information
Criterion (AIC) [Akaike (1973, 1983a, 1983b)]. Hoeting et al. (1999) pro-
vide examples where the use of BIC in Bayesian model selection and model
averaging leads to excellent predictive performance in practice.
Models M correspond to different choices of features and polynomials in
the features used to capture the smooth functions. Using BIC, the probabil-
ity of a model,Mm, given the collection of panel dataY = {Yij}i=1,...,n,j=1,...,J
is approximated by
p(Mm|Y) =
exp(L(Mm)− (dm/2) log(n))∑
m′ exp(L(Mm′)− (dm′/2) log(n))
,
where L(Mm) is the log likelihood under modelMm evaluated at the max-
imum likelihood estimates βˆ and dm is the number of terms in the model.
Because of the large number of features and higher order terms, we cannot
enumerate all models. To identify the high posterior probability models, we
used the deterministic search algorithm bic.glm() in S-PLUS [Hoeting et
al. (1999)].
Because of the large number of potential features and limitations in the
leaps and bounds algorithm used in bic.glm(), it was necessary to use a
two stage procedure to identify which features would be incorporated in the
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selected model. The first stage was a screening stage where we identified the
highest probability models that included only linear terms in the features.
Using the subset of features that were included in the top model, we then
added quadratic and cubic terms in these features, and repeated the calcula-
tions of the posterior model probabilities. While such a sequential approach
may miss the highest probability model,6 this scheme corresponds to a hi-
erarchical model that incorporates second order (and higher) terms only if
there are important main (linear) terms. Second, because the search algo-
rithm needed to be run for hundreds of other drugs, this led to a reasonably
efficient computational strategy. After this two stage selection approach, the
highest posterior probability model was used to determine the distribution
of the MIC, as described in Section 4.
The above procedures are applied to study the turbidity and redox growth
curves for gram-negative bacterial strains exposed to dilutions of cefoxitin
(FOX) (n = 1647 panels) and piperacillin (PIP) (n = 1599 panels). These
two antibiotics were selected to provide a testbed for method development.
FOX was considered to be an easier system to model, with more clearly
distinguished cases of GROWTH/NO GROWTH, while PIP was viewed as
being a more challenging case, as illustrated with the selected growth curves
in Figure 1. For modeling purposes here, both fast and slow growing strains
were combined. The data for FOX were obtained using the following series
of two-fold dilutions {2−1,20,21, . . . ,25} (J = 7), while the data for PIP used
{2−2,2−1, . . . ,27} (J = 10).
The selected features are dependent on the drug. The model for FOX in-
cludes five terms: T.FD.M.R the ratio of the turbidity maximum first deriva-
tive of the test well to the turbidity maximum first derivative of the control
well; R.FD first derivative of redox in the test well; R.SD second derivative
of redox in the test well; R.SD.M maximum second derivative of redox in the
test well; and R.AB.M.R the ratio of the redox maximum absolute value of
the test well to the redox maximum absolute value of the control well. The
model for the more challenging PIP data includes nine terms: an T.AB.M.R
the ratio of the turbidity maximum absolute value of the test well to the
turbidity maximum absolute value of the control well; T.FD first derivative
of turbidity in the test well; T.SD second derivative of turbidity in the test
well; T.FD.M.R ratio of absolute first derivative of turbidity of the test well
to maximum first derivative of turbidity in the control well; T.SD.M maxi-
mum second derivative of turbidity in the test well; R.AB.M.R the ratio of
the redox maximum absolute value of the test well to the redox maximum
absolute value of the control well; R.FD first derivative of redox in the test
6If there are strong quadratic or cubic effects, but the linear terms are not important,
then we may fail to select this model with the sequential approach.
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well; R.FD.M.R ratio of absolute first derivative of redox of the test well
to maximum first derivative of redox in the control well; and R.SD second
derivative of redox in the test well.
In modeling GROWTH/NO GROWTH, we made no provision to order
the estimated probabilities piij in panel i according to dilution. Rather than
explicitly building an order constraint into the model for GROWTH/NO
GROWTH, we take the theoretical ordering into account in developing the
prediction of the MIC, as described in the next section.
4. MIC estimation.
4.1. Overview of MIC estimation. The modeling described in Section 3
operates at the level of a single dilution or well in a panel, and is aimed at
determining the probability that each dilution is displaying growth. Note,
however, that prediction of the MIC must be done at the level of a panel.
In this section we describe our strategy for combining the dilution-level
predictions and obtaining a MIC estimate for each panel. For panel i, our
prediction algorithm consists of the following steps:
Estimate growth probabilities. For each dilution j in panel i estimate the
probability piij that there is growth, pˆiij .
Combine growth probabilities. For each dilution j in panel i estimate the
probability ρij that dilution j is the MIC. This distribution of the MIC is
constructed by combining all the pˆiij for panel i and is described in detail
in Section 4.2.
Estimate the MIC. Using the distribution of the MIC in panel i, ρij , derive
an estimate for the MIC for the panel. Two estimates are discussed in
detail: the “modal MIC” and a “decision theoretic MIC.” The probability
distribution of the MIC may also be used to delay the call, when there is
a high degree of uncertainty about which dilution is the MIC.
Statistically, this overall procedure achieves the important practical goals
of (a) estimating growth based on simple physical features representing
growth in a well; (b) training the growth probability model on large data
sets; (c) adjusting the probability of growth in a well depending on the ob-
servations made on other wells in the same panel; and (d) providing the
basis for sequential estimation of the MIC, and decisions about delaying the
call.
4.2. Probability distribution of the MIC. We now describe how to derive
the probabilities ρi1, . . . , ρiJ+1 that dilution j is the MIC of the ith panel,
using the set of probabilities pˆii1, . . . , pˆiiJ that there is growth in each well.
Suppose that the dilution for well j (denoted as Dj) is the MIC for panel
i. If this were true, theoretically we would have the following sequence of
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curves: all curves with dilutions less than Dj would exhibit GROWTH, and
all dilutions greater than or equal to Dj would have NO GROWTH. How
do we compute the probability of this sequence given the probability of
GROWTH/NO GROWTH for each well?
First, we make additional assumptions of order (O) and independence
(I):
O: Suppose that the dilution (concentration) in well j, Dj , is greater than
the dilution in well k, Dk. Then, if Dk is inhibitory, so is Dj .
I: Conditional on the set of probabilities piij for j = 1, . . . , J , the outcome
in well j, Yij is independent of the outcome Yik in any other well k 6= j.
We utilized Assumption I in constructing the model for GROWTH/NO
GROWTH. Within the nested restrictions of Assumption O, the probability
of the sequence of curves that can lead toDj being the MIC can be computed
under independence, Assumption I.
Consider the set of all sequences of growth curves that satisfy the ordering
Assumption O. We call these “valid” sequences. For example, if a panel had
only three wells, the set of valid sequences of GROWTH/NO GROWTH
results would be
D1 < D2 < D3 Call
0 0 0 MIC ≤D1
1 0 0 D1 <MIC ≤D2
1 1 0 D2 <MIC ≤D3
1 1 1 MIC >D3
.
Note that while there are J dilutions, there are J +1 valid sequences, since
if all J observed curves exhibit growth, the call should be that the MIC is
greater than the highest observed dilution.
By restricting attention to the reduced set of ordered sequences, we are
now in a position to compute the probability ρij of the sequence of curves
that leads to Dj being the MIC in panel i. This ordered sequence is
D1 . . . Dj−1 Dj . . . DJ
1 1 1 0 0 0 .
By comparing the likelihood of the sequence above to the likelihood of the
other valid sequences, we can compute MIC probabilities that are consistent
with the ordering Assumption O,
ρij = P (Dj−1 <MIC i ≤Dj) =
∏
k<j piik
∏
k≥j(1− piik)∑J+1
j=1
∏
k<j piik
∏
k≥j(1− piik)
(4.1)
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for j = 1, . . . , J +1, where the denominator is a sum over all J +1 valid se-
quences and for notational convenience, D0 ≡ 0 and DJ+1 ≡∞. This frame-
work allows us to predict that the MIC is greater than any of the observed
dilutions, which is important in detecting emerging resistance.
For a particular modelMm, these probabilities are estimated by plugging
in the pˆiij . To take into account model uncertainty, one can average the above
expression over several models using the posterior probabilities of models as
weights. While such a procedure may give better estimates, we have not
pursued this direction because of the computational demands associated
with on-line implementations, and instead use the highest probability model.
The probabilities ρij can be used in several ways to determine an estimate
of the MIC. We experimented extensively with two approaches: the “modal
MIC” and a “decision theoretic MIC.” The modal MIC consists simply of
choosing the dilution Dj for panel i with the largest probability ρij . This
is the optimal estimator under a loss function that is one if the estimate is
not the true MIC and zero if the estimate is exactly the MIC. Our decision
theoretic MIC takes into account that under-estimation and over-estimation
have different costs and that errors of plus or minus one dilution are unim-
portant.
4.3. Decision theoretic MIC estimation. In evaluating performance in
practice, a number of error types are evaluated. The essential agreement be-
tween an estimated MIC and reference MIC is defined as agreement in MIC
to within ± one two-fold dilution. According to the Food and Drug Admin-
istration (FDA) [FDA (2007), page 21], the essential agreement should be
greater than or equal to 90%. In general, underestimation of the MIC by
more than one dilution is considered to be worse than overestimating the
MIC by more than one dilution.
A second approach for evaluating performance utilizes the categorical clas-
sification of isolates as susceptible, intermediate or resistant (SIR). The SIR
interpretations are compared and categorical agreement is evaluated. Based
on FDA guidelines, the overall categorical agreement should be greater than
or equal to 90%. Acceptable error rates are based on the clinical significance
of the error. A very major error occurs when an isolate is called susceptible
when the isolate is in fact resistant. A very major error rate greater than
1.5% of the resistant strains would be unacceptable. The major error thresh-
old is more forgiving, less than or equal to 3%, and occurs when an isolate
is called resistant when in actuality the isolate is susceptible. We devise a
decision theoretic estimator that captures the ideas behind the categorical
errors, where underestimating the MIC leads to more severe consequences
than overestimating it. One way to capture this is to attach a weight, or a
loss, to each dilution error size. We use the following notation:
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Error Loss
Exact prediction (no error) 0
Predicted MIC within 1 dilution of reference MIC w3
Predicted MIC > reference MIC by more than 1 dilution w2
Predicted MIC < reference MIC by more than 1 dilution w1
.
The w’s need to be chosen to reflect the relative importance of the errors
and will typically be such that w1 >w2 >w3.
To obtain the MIC prediction, we choose the dilution that minimizes the
expected loss. For dilution Dj this is
Lj =w1
∑
k>j+1
ρik +w2
∑
k<j−1
ρik +w3(ρi(j−1) + ρi(j+1)).(4.2)
The decision theoretic MIC prediction is the Dj associated with the j that
minimizes Lj . If one chooses w1 =w2 =w3, the modal MIC and the decision
theoretic MIC coincide. For the analyses reported later we used w1 = 5,w2 =
1 and w3 = 0, reflecting that underestimating the MIC by more than one
dilution is 5 times worse than overestimating it by more than one dilution.
There is no penalty for being within one dilution of the reference MIC.
4.4. Uncertainty and making a call. The distribution of the MIC may
be useful in formulating guidelines for deciding when to make a call on the
MIC prediction or when to continue incubating a panel. One could deter-
mine the modal MIC or decision theoretic MIC and how much probability
they receive, as well as how much probability mass the estimated MIC plus
or minus 1 dilution receives. Sampling could continue until these reach a
specified level. We expect that, as sampling continues, the estimated piij will
become closer to 1 or 0, so that the probability of the model MIC (the di-
lution with the largest probability) should increase to 1. However, early on
the probabilities will not be as concentrated.
4.5. Illustration. Figure 2 shows the MIC distribution for the three bac-
terial strains that were presented in the growth curves in Figure 1, while
Table 2 lists the estimates of the MIC and the probability mass that they
receive.
For strain 14,482, the distribution of the MIC is uni-modal with a peak at
two, which corresponds to the modal MIC, the decision theoretic MIC and
the reference MIC. For strain 14,598, we also have a uni-modal distribution,
but underestimate the MIC by one dilution using the modal MIC (reference
MIC = 2, modal MIC = 1), while the decision theoretic MIC agrees with
the reference MIC. Because the estimate is within one dilution of the refer-
ence MIC, this error is not important for essential agreement. Finally, for
strain 14,617, the modal MIC is 128, while the reference MIC is 4. While
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Fig. 2. Probability distribution of the MIC for the three strains presented in Figure 1.
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Table 2
MIC prediction results for the three strains of interest. P(REF ± 1) represents the
probability of the mass assigned to dilutions within 1 two-fold dilution of the reference
MIC. P(modal MIC) and P(DT MIC) are the probabilities that the modal and the
decision theoretic MICs estimates are the MIC, respectively. P(valid sequence) is the sum
of probabilities of all possible valid sequences
REF MIC Modal MIC Decision theoretic MIC
Test ID P(REF ± 1) P(modal MIC) P(DT MIC) P(valid sequence)
14,482 2 2 2 0.33
(0.96) (0.54) (0.54)
14,598 2 1 2 0.27
(0.97) (0.66) (0.26)
14,617 4 128 128 0.85
(0.00) (0.54) (0.54)
overestimation of the MIC is better than underestimation, this results in an
unacceptably large error. Verification of the reference data indicated that
the response variable is in fact not in error, but that the problem is likely
with the particular panel and/or isolate. The reference MIC and dilutions
within one of it receive virtually no support under the estimated distribu-
tion of the MIC for strain 14,617, however, for strains 14,482 and 14,598, the
probability that the MIC is within one dilution of the reference MIC is 0.96
and 0.97 respectively. Also of interest to note is that for strains 14,482 and
14,598, although the predictions are in agreement with the reference MIC,
the probability of the growth sequence being valid is low compared to strain
14,617. While the growth patterns may deviate from the valid order as de-
fined by the respective drug dilutions, this probability does not necessarily
provide a reliable indication of the accuracy of the estimated MIC.
5. Validation. To carry out model validation for each drug, we divide the
data into a training and validation group. We used a random sample of 65%
of the panel data for training and the remaining 35% for validation. In the
training stage we identify the best model using BIC as described previously.
This model is then used to predict the MICs for the validation group.
The MIC prediction for the validation group proceeds as follows:
1. The features from each dilution j of each panel i in the validation group
are used along with the estimated coefficients from the training data to
estimate the probability of growth, piij , for dilution j, pˆiij .
2. The probability that a dilution is the MIC for panel i, ρˆij is calculated
[see equation (4.1)]. These probabilities are estimated by plugging in the
estimates of piij obtained in Step 1 for each panel in the validation set.
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3. The estimated MIC probabilities (ρˆij , j = 1, . . . , J + 1) are then used to
estimate the modal or decision theoretic MIC for panel i.
For each panel in the validation set we thus obtain a modal and decision
theoretic MIC estimator.
5.1. Essential agreements. The essential agreements for the FOX nd PIP
data are summarized graphically in Figures 3 and 4 and in Tables 3 and 4.
In Figures 3 and 4, the choice of MIC estimator affects the error rates. For
the modal MIC in FOX, the error rate associated with underestimation by
more than one two-fold dilution was 3.82%, whereas for the decision theo-
retic MIC, the underestimation error rate was 1.56%. Essential agreements
for the two MIC estimates were similar, 93.23% for the modal MIC and
93.40% for the decision theoretic MIC. The error rates for PIP are notice-
ably higher, as anticipated, based on initial perceptions of PIP being a more
challenging system. There is a greater tendency for the modal MIC estimate
to underestimate the MIC with PIP, than what was observed with FOX.
For PIP, the decision theoretic MIC has a much higher essential agreement
Fig. 3. Essential agreement (top) and log2 residual plots (bottom) for the FOX validation
set using the modal MIC (left) and the decision theoretic MIC (right).
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Fig. 4. Essential agreement (top) and log2 residual plots (bottom) for the PIP validation
set using the modal MIC (left) and the decision theoretic MIC (right).
than the modal MIC, with a reduction by half in the underestimation error
rate (12.14% versus 23.57%).
To further explore the errors, plots of log2(estimated MIC) − log2(reference
MIC) versus the expected loss evaluated at the estimated MIC are given in
Figures 3 and 4, where the estimated MIC is either the modal MIC or de-
cision theoretic MIC. For the modal estimate the corresponding loss is one
minus the probability that the modal MIC is the true MIC, 1 − P(modal
MIC), and the loss at the decision theoretic MIC, L(DT MIC), is given by
equation (4.2). These plots suggest better agreement between the estimated
and reference MIC when the probability of modal MIC is high or loss at the
decision theoretic MIC is low. We therefore examined the essential agree-
ments for strains where the probability of the modal MIC was at least 0.5.
This leads to a slight improvement for FOX (essential agreement is 94.1%
and 94.9% for the modal and decision theoretic estimators, resp.). The gains
are greater for PIP with essential agreements of 74.3% and 85.0%, for the
modal and decision theoretic estimators, respectively. This suggests that it
is possible that by delaying the call because of substantial uncertainty in the
MIC and allowing the samples to incubate longer, that we may reduce some
of the large errors. This is particularly important for resistant strains that
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Table 3
Essential agreements from the FOX validation data
Estimate EST−REF < −1 −1 ≤ EST−REF ≤ −1 EST−REF > 1
Modal MIC 3.82 93.23 2.95
Decision theoretic MIC 1.56 93.40 5.03
Table 4
Essential agreements from the PIP validation data
Estimate EST−REF < −1 −1 ≤ EST−REF ≤ −1 EST−REF > 1
Modal MIC 23.57 71.07 5.36
Decision theoretic MIC 12.14 79.82 8.04
exhibit delayed growth. By delaying the call, the resistance may become
more pronounced, leading to correct classification of the curves.
6. Discussion. In this paper we have illustrated a probabilistic approach
for estimating MICs based on panels of microbial growth curves. Given the
necessity to fit a large number of models to hundreds of antibiotics for the
implementation in PHOENIX, we had to make several compromises in our
modeling approach at the time of algorithm development due to the avail-
able computational environments and the computing/storage constraints of
the PHOENIX device. Given advances in computing environments today,
more flexible models could be obtained by replacing the cubic polynomials
with piecewise cubic splines as in generalized additive models. While a fully
Bayesian analysis that accounts for errors in the reference MIC might be
preferable, the use of logistic regression with approximate model probabil-
ities using BIC and plug-in estimates provided a reasonable solution that
could be implemented in real-time in a device with limited computing and
storage capacity.
The experimental data presented in this paper to illustrate MIC determi-
nation were from the early stages of development of the PHOENIX system.
Since our initial analyses were conducted, BD refined formulation of pan-
els and the potencies were adjusted to provide optimum concentrations of
antimicrobial agents, leading to a reduction in the bias noted here in PIP.
Currently, the methodology described in this paper for the modal MIC is
used to make an initial estimate of the MIC in PHOENIX. There are two
additional steps in PHOENIX that are used before making a final MIC de-
termination that affect very major and major errors. The first is an expert
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system that determines if the time is long enough for resistance to express
(delayed resistance detection). The second step uses an expert system that
takes the results and combines them with other data (resistance markers)
to provide a final MIC and SIR determination.
To date, more than seventy-five recent studies have shown the PHOENIX
AST system provides accurate estimates of MICs and susceptibility inter-
pretation for various micro-organisms and drugs [see, e.g., Fahr et al. (2003),
Donay et al. (2004), Horstkotte et al. (2004)]. Currently, 85 drugs are cleared
by the FDA in the U.S. having met FDA standards for essential and categor-
ical agreement, with an additional 20 to 25 in clinical trials. In a European
collaborative two-center trial [Fahr et al. (2003)], this system was tested for
469 clinically obtained bacterial isolates with 64 antimicrobial drugs. The re-
sults were compared to those of frozen standard broth micro-dilution panels
according to the guidelines of the Clinical and Laboratory Standards Insti-
tute (formerly the National Committee for Clinical Laboratory Standards).
The study [Fahr et al. (2003)] found that performance of the PHOENIX
AST system was equivalent to that of the standard broth micro-dilution
reference method. In addition to accuracy in prediction, the study [Donay
et al. (2004)] found that the PHOENIX AST system required significantly
less time to obtain results than by the disk diffusion method.
Predicting the emergence of antibiotic resistance is a challenging prob-
lem that many automated AST systems fail to adequately address [Tenover
et al. (2006)]. In some cases resistance to higher levels of an antibiotic is
virtually unknown. Because the models developed in this paper predict in-
hibition of growth based on features of the curves, and not actual dilution,
the PHOENIX AST system may predict high MICs indicative of emerging
resistance, even though the models have not necessarily been trained on
resistant strains. For example, the PHOENIX system has already proved
to be effective in detecting the emergence of Staphylococcal resistance to
vancomycin [Deal et al. (2002)].
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